摘要
采用前瞻性及自身交叉对照 2种调查设计方法对国产及进口重组人粒细胞巨噬细胞集落刺激因子 (rHuGM CSF)进行了血液肿瘤病人化疗后升白细胞的临床疗效及药物经济学评价。结果证明 2组临床疗效即升白细胞效果无显著性差异。最小成本法比较 ,如果应用国产品其期望有效治疗成本平均每例可节省人民币 70 0 0～ 2 0 0 0 0元。
A prospective and a selfcross control clinical trial and pharmacoeconomic study were conducted respectively in two groups of hematologic malignancies patients by using domestic rHuGMCSF product (Topleucon) and imported one (Leucomax). The results showed that there were no significant difference in both clinical efficacy and raising the amount of leucocytes in the two groups. The minimum cost analysis illustrated that the expected cost of 100 % effective treatment per patient in Topleucon group is 7, 000～20,000 yuan (RMB) less than that in Leucomax group.
出处
《中国新药与临床杂志》
CSCD
北大核心
2000年第4期309-312,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
RHUGM-CSF
白血病
药学经济学
granulocyte-macrophage coloy-stimulating factor
leukemia
pharmaceutical economics
